Archive

Posts Tagged ‘biotech ETFs’

The Top Biotech ETF To Buy Right Now

June 15th, 2015

biotechKyle Anderson: Our favorite biotech ETF has been one of the biggest winners of this sector’s 2015 rally… Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:FBT

Changing The Face Of Biotech Investing

June 1st, 2015

biotechLawrence Meyers: If you’re interested in seeking out investments in new biotechnology and pharmaceutical advances that could change the face of health care, then you may want to look at some ETFs that may take advantage of the advance in biosimilars. Read more…

NASDAQ:IBB, NYSE:PPH

Pharma’s Record Setting First Quarter

May 12th, 2015

biotechKyle Anderson: The pharmaceutical industry saw record-setting M&A activity in the first quarter of 2015. Read more…

NYSE:XPH

Amgen, Inc., Gilead Sciences, Inc., Biogen Inc, Celgene Corporation: Is A Biotech Bubble Looming?

April 14th, 2015

dollar money bubbleJay Taylor: If you own shares of biotechnology stocks, chances are you’re having a great 2015. Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:FBT

Gilead Sciences, Inc., Amgen, Inc., Biogen Inc: Is This A Biotech Bubble?

April 1st, 2015

dollar money bubbleKyle Anderson: Wall Street pundits are claiming we are on the precipice of a biotech bubble because biotechnology stocks have been soaring. Read more…

NASDAQ:BIB, NASDAQ:IBB

2015 Biotech ETF Surge Reflects Healthy Sector

March 23rd, 2015

biotechJim Bach: Popular biotech ETF First Trust NYSE Arca Biotechnology Index Fund (NYSE Arca: FBT) is up 23.5% on the year. It’s among our top performing picks for year-to-date performance from our “stocks to invest in” list. Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:FBT

The Best Biotech ETF To Buy and One To Avoid

October 14th, 2014

biotechKyle Anderson:  A biotech ETF (exchange-traded fund) is an excellent way to capture profits from the entire industry with just one investment. Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:FBT

Biotechs With Massive Upside

September 15th, 2014

biotechEverybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. Read more…

NASDAQ:BIB, NASDAQ:IBB

ETF Impact On Biotech Earnings

July 31st, 2014

biotechnologyThe Q2 earnings season has so far been great for biotech companies with most of them giving solid quarterly updates. Biotech giant Gilead Sciences (GILD) continued with its exceptional performance in this quarter as well, beating the Zacks Consensus Estimate Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:BBH, NYSE:PJP

Biotechs With High Reward Potential

July 31st, 2014

biotechA biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings Read more…

NASDAQ:BIB, NASDAQ:IBB

Gilead Sciences, Inc. (GILD): The Bullish Case For The Stock

July 28th, 2014

biotechKyle Anderson: Gilead Sciences Inc. (NASDAQ:GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, GILD stock has climbed 3% from yesterday’s close. Read more…

NASDAQ:BIB, NASDAQ:IBB

Why I’m Bullish On Gilead Sciences, Inc. (GILD)

July 28th, 2014

bullish buyTyler Laundon: Biotech bears were tearing apart the sector in Q1 of this year. And it got ugly. Read more…

NASDAQ:BIB, NASDAQ:IBB

Invest In These Alternatives To Biotech

July 23rd, 2014

biotechnologyBill Hall:  The alarm bells went off on Wall Street last week as Federal Reserve Chair Janet Yellen warned of a bubble in social media and biotech stocks. Indeed, in her public comments last week, Yellen stated that biotechnology valuations are “stretched, Read more…

NASDAQ:IBB

The Biggest Beneficiary Of Biotech’s Comeback

July 10th, 2014

money and investingMichael Robinson: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.” Read more…

NASDAQ:BIB, NASDAQ:IBB

The Biotech Bull Market Is Far From Over

July 10th, 2014

biotechThe biotech bull market is not over. That’s the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. Read more…

NASDAQ:BIB, NASDAQ:IBB




Copyright 2009-2015 WBC Media, LLC